IR Contacts | Ocular Therapeutix, Inc.

Skip to main navigation

FDA approves DEXTENZA^® for the treatment of ocular inflammation

About
Pipeline
Products
- DEXTENZA^®
- ReSure® Sealant
Investors
Investor Relations
Careers
- Core Values + Benefits
- Open Positions
Search

IR Contacts

Donald Notman
Chief Financial Officer
E-mail: dnotman@ocutx.com

Westwicke Partners on behalf of Ocular Therapeutix
Christopher F. Brinzey
339.970.2843
E-mail: chris.brinzey@westwicke.com

Shareholder Tools

Print
E-mail
RSS
Share
Alerts
Contact

Share on:
Facebook
Twitter
LinkedIn
Google+
Google

Ocular Therapeutix, Inc.15 Crosby DriveBedford, MA01730Phone: 1-877-628-8998

The use of this Site is governed by its Terms of Use. The information contained in this Site is for informational purposes only. It is not a substitute for professional medical advice and should not be used to diagnose or treat any medical or health condition.

The contents of this Site are subject to change without notice. Ocular Therapeutix may modify and/or discontinue operation of all or portions of this Site at any time at its sole discretion without notice, and assumes no responsibility to update this Site. Ocular Therapeutix makes no representations or warranties with respect to the use of this Site or any information obtained herein.